- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01614743
A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
This is a double-blinded, randomized placebo controlled pilot study comparing the efficacy and safety of incobotulinumtoxinA versus saline injections to the cheek region in patients with rosacea.
The pilot study will enroll and treat a total of 10 subjects who present with rosacea of the cheek area. Upon study entry, subjects will be randomized to receive treatment with incobotulinumtoxinA or bacteriostatic saline to the cheek area. Study treatment will be prepared by an unblinded designee and both Physician Investigator (PI) and subject will remain blinded for the duration of the study. At the 16 week visit, control subjects will enter the rescue arm portion of the study and all study subjects will receive treatment with incobotulinumtoxinA to the cheek areas.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- DeNova Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females between 18 and 65 years of age.
- Subjects presenting with rosacea in the cheek area.
- Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:
- postmenopausal for at least 12 months prior to study drug administration
- without a uterus and/or both ovaries
- has had a bilateral tubal ligation for at least 6 months prior to study drug administration.
- absence of an other physical condition according to the PI's discretion
- Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).
- Willingness and ability to provide written informed consent prior to performance of any study related procedure.
Exclusion Criteria:
- Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
- Subjects with a known allergy or sensitivity to any component of the study medications or anesthesia.
- Topical or oral rosacea treatments within the past 2 weeks.
- Subjects with a significant systemic illness or illness localized to the areas of treatment.
- Botulinum toxin to the face within the past 6 months.
- Significant concurrent illness such as diabetes, epilepsy, lupus, or congestive heart failure.
- Concurrent skin condition affecting area to be treated.
- Prior surgery on the area to be treated within 3 months of initial treatment or during the study.
- History or evidence of keloids or hypertrophic scarring.
- Subjects currently using aminoglycoside antibiotics, curare-like agents or other agents that might interfere with neuromuscular function.
- Subjects with a diagnosis of Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function or current facial palsy.
- Current history of chronic drug or alcohol abuse.
- Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
- Subjects who, in the Investigator's opinion, have a history of poor cooperation, non¬compliance with medical treatment or unreliability.
- Enrollment in any active study involving the use of investigational devices or drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Placebo at baseline, incobotulinumtoxinA at 16 weeks
|
EXPERIMENTAL: IncobotulinumtoxinA
|
Experimental injection given at baseline and Week 16
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in the Rosacea Clinical Score Card
Time Frame: baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Live rosacea assessment for each side of the face using the Rosacea Clinical Scorecard for clinical assessment.The Rosacea Clinical Scorecard assesses the primary signs and symptoms of rosacea and is graded as absent (0), mild (1), moderate (2) or severe (3).
|
baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Number of Participants Experiencing Adverse Events
Time Frame: baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Rate of adverse events
|
baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Heatherton & Polivy State Self-Esteem (HPSS) Scale Score at Baseline, 1, 4, 12, 16, 17, and 20 Weeks
Time Frame: baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Self-esteem change will be determined by patient self-evaluation using the Heatherton & Polivy State Self-Esteem (HPSS) Scale. Heatherton & Polivy State Self-Esteem (HPSS) Scale includes three facets of self-esteem: Appearance, Performance, and Social The scale has a range of 20-100. A score closer to 100 signifies higher self-esteem, while a score closer to 20 signifies lower seld-esteem. |
baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Patient Satisfaction
Time Frame: week 1, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
4-point categorical assessment of patient satisfaction with treatment.
|
week 1, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROS-INC-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
Clinical Trials on IncobotulinumtoxinA
-
Merz Pharmaceuticals GmbHCompletedCervical DystoniaUnited States
-
Merz Pharmaceuticals GmbHTerminatedHabitual SnoringGermany
-
Merz Pharmaceuticals GmbHCompletedPost-stroke Upper Limb SpasticityCzech Republic, Hungary, Poland
-
Merz Pharmaceuticals GmbHCompletedCerebral Palsy | SpasticityPoland, Russian Federation, Ukraine, United States, Argentina, Mexico
-
Yale UniversityMerz North America, Inc.Terminated
-
Merz Pharmaceuticals GmbHCompletedLower Limb Spasticity Due to Cerebral PalsyPoland, Austria, Czechia, Estonia, France, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine
-
Wake Forest University Health SciencesMerz Pharmaceuticals GmbHRecruiting
-
Merz Pharmaceuticals GmbHCompletedSpasticity of the Upper and Lower Limb Due to Cerebral CausesGermany, United States, Canada, France, Italy, Norway, Portugal, Spain
-
King, David, MDMERZ PHARMANot yet recruitingWhiplash Injuries | Thoracic Outlet SyndromeCanada
-
Clinical Testing of Beverly HillsMerz North America, Inc.Not yet recruiting